Yeon-Sook Kim, Jun Yong Choi, Dae Won Park, Shin-Woo Kim, Tae Hyong Kim, Julie Ryu, Rebecca Harrison, Jeong-A Lee, Flora Park, Sun Hee Lee
{"title":"BICSTaR的24个月数据显示，比替格拉韦/恩曲他滨/替诺福韦在韩国HIV感染者中的有效性和安全性","authors":"Yeon-Sook Kim, Jun Yong Choi, Dae Won Park, Shin-Woo Kim, Tae Hyong Kim, Julie Ryu, Rebecca Harrison, Jeong-A Lee, Flora Park, Sun Hee Lee","doi":"10.3947/ic.2025.0061","DOIUrl":null,"url":null,"abstract":"<p><p>BICtegravir Single Tablet Regimen is a multi-national observational cohort study evaluating the effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in people with human immunodeficiency virus. We present 24-month data from participants in Korea. Eighty-eight participants (36 treatment-naïve [TN], 52 treatment-experienced [TE]) were included. At 24 months, 100% (29/29) of TN and 100% (37/37) of TE participants had HIV-1 RNA <50 copies/mL (missing=excluded analysis). BIC/FTC/TAF persistence was 100% (33/33) and 96.1% (49/51) in TN and TE participants, respectively. Drug-related adverse events occurred in 2 TN participants. Improvements in some patient-reported outcomes were observed. BIC/FTC/TAF maintained effectiveness, persistence, and tolerability over 24 months.</p>","PeriodicalId":51616,"journal":{"name":"Infection and Chemotherapy","volume":" ","pages":"424-430"},"PeriodicalIF":2.9000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12511748/pdf/","citationCount":"0","resultStr":"{\"title\":\"Effectiveness and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide in People with HIV in Korea: 24-Month Data from BICSTaR.\",\"authors\":\"Yeon-Sook Kim, Jun Yong Choi, Dae Won Park, Shin-Woo Kim, Tae Hyong Kim, Julie Ryu, Rebecca Harrison, Jeong-A Lee, Flora Park, Sun Hee Lee\",\"doi\":\"10.3947/ic.2025.0061\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>BICtegravir Single Tablet Regimen is a multi-national observational cohort study evaluating the effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in people with human immunodeficiency virus. We present 24-month data from participants in Korea. Eighty-eight participants (36 treatment-naïve [TN], 52 treatment-experienced [TE]) were included. At 24 months, 100% (29/29) of TN and 100% (37/37) of TE participants had HIV-1 RNA <50 copies/mL (missing=excluded analysis). BIC/FTC/TAF persistence was 100% (33/33) and 96.1% (49/51) in TN and TE participants, respectively. Drug-related adverse events occurred in 2 TN participants. Improvements in some patient-reported outcomes were observed. BIC/FTC/TAF maintained effectiveness, persistence, and tolerability over 24 months.</p>\",\"PeriodicalId\":51616,\"journal\":{\"name\":\"Infection and Chemotherapy\",\"volume\":\" \",\"pages\":\"424-430\"},\"PeriodicalIF\":2.9000,\"publicationDate\":\"2025-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12511748/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Infection and Chemotherapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3947/ic.2025.0061\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/9/9 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Infection and Chemotherapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3947/ic.2025.0061","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/9/9 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
Effectiveness and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide in People with HIV in Korea: 24-Month Data from BICSTaR.
BICtegravir Single Tablet Regimen is a multi-national observational cohort study evaluating the effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in people with human immunodeficiency virus. We present 24-month data from participants in Korea. Eighty-eight participants (36 treatment-naïve [TN], 52 treatment-experienced [TE]) were included. At 24 months, 100% (29/29) of TN and 100% (37/37) of TE participants had HIV-1 RNA <50 copies/mL (missing=excluded analysis). BIC/FTC/TAF persistence was 100% (33/33) and 96.1% (49/51) in TN and TE participants, respectively. Drug-related adverse events occurred in 2 TN participants. Improvements in some patient-reported outcomes were observed. BIC/FTC/TAF maintained effectiveness, persistence, and tolerability over 24 months.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
